FINNENCE ▪ THE WIRE FILE
THE WIRE · № 70006
SEC Filing■ Unclear/unknown
META filed 4 on 2026-10-07
KINDSEC Filing
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN2026-10-07 00:00 UTC
LAST UPDATE2026-10-07 00:00 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
A Form 4 discloses insider transactions; without share counts, price, or buy/sell direction, no signal can be read.
Routine insider filing with no disclosed transaction details
CATALYST TO WATCH
Follow-up disclosure of shares and transaction code
MAIN RISK
Details may reveal insider selling pressure
FULL DISPATCH
META (CIK 0001564475) filed a 4 on 2026-10-07.
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
SUBJECTMeta Platforms · META
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→INFERENCEfilings generate company commentary
New Phase 3 trial: J-LINX: Japan LINerixibat eXtension Study — GlaxoSmithKline2026-10-06 12:00 UTC
New Phase 3 trial: J-LINX: Japan LINerixibat eXtension Study — GlaxoSmithKline2026-10-06 12:00 UTC
→INFERENCEfilings generate company commentary
New Phase 3 trial: A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity — Novo Nordisk A/S2026-10-06 12:00 UTC
New Phase 3 trial: A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity — Novo Nordisk A/S2026-10-06 12:00 UTC
→INFERENCEfilings generate company commentary
New Phase 3 trial: Phase 3 Evaluation of Sovateltide for the Treatment of Acute Traumatic Brain Injury — Pharmazz, Inc.2026-10-06 12:00 UTC
New Phase 3 trial: Phase 3 Evaluation of Sovateltide for the Treatment of Acute Traumatic Brain Injury — Pharmazz, Inc.2026-10-06 12:00 UTC
→INFERENCEfilings generate company commentary
Phase 3 results posted: A Study Testing the Use of a Perivascular Sirolimus Formulation (Sirogen) in ESRD Patients Undergoing AV Fistula Surgery — Vascular Therapies, Inc.2026-10-06 12:00 UTC
Phase 3 results posted: A Study Testing the Use of a Perivascular Sirolimus Formulation (Sirogen) in ESRD Patients Undergoing AV Fistula Surgery — Vascular Therapies, Inc.2026-10-06 12:00 UTC
→INFERENCEfilings generate company commentary
Phase 3 results posted: A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) — Janssen Research & Development, LLC2026-10-06 12:00 UTC
Phase 3 results posted: A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) — Janssen Research & Development, LLC2026-10-06 12:00 UTC
→INFERENCEfilings generate company commentary
New Phase 3 trial: Phase 3 Study of Denifanstat in Participants With Moderate to Severe Acne — Sagimet Biosciences Inc.2026-10-07 12:00 UTC
New Phase 3 trial: Phase 3 Study of Denifanstat in Participants With Moderate to Severe Acne — Sagimet Biosciences Inc.2026-10-07 12:00 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.